Nab-paclitaxel in combination with Bevacizumab in patients with non-squamous non-small cell lung cancer after failure of at least one prior systemic regimen

Background: Most patients with non-small cell lung cancer (NSCLC) experience disease progression after first-line treatment. The efficacy and safety of the nab-paclitaxel (nab-PTX) and bevacizumab combination as the second or further line of treatment in patients with advanced NSCLC have not been re...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Cancer
Hlavní autoři: Hao, Xuezhi, Zhu, Yixiang, Mu, Yuxin, Wang, Shouzheng, Li, Junling, Xing, Puyuan
Médium: Artigo
Jazyk:Inglês
Vydáno: Ivyspring International Publisher 2020
Témata:
Research Paper
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7532494/
https://ncbi.nlm.nih.gov/pubmed/33033525
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7150/jca.47072
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky